Shots:

• The collaboration leverages Regeneron's VelociSuite technologies including the VelocImmune platform to develop mAb as monothx. or in combination to treat coronavirus (2019-nCoV)
• In 2017- HHS and Regeneron collaborated for discovery- research- development and manufacturing of an Abs targeting up to 10 pathogens including influenza virus and 2019-nCoV
• Regeneron's VelociSuite technologies including the VelocImmune platform utilizes a unique genetically engineered mouse with a humanized immune system- accelerating swift identification- preclinical validation and development Ab therapies

Click here ­to­ read full press release/ article | Ref: Regeneron  | Image: The Pharma Letter